Treovir announces opening of G207 Phase 2 clinical trial in children with recurrent brain tumors.
December 4, 2024. Birmingham, AL. Treovir, Inc. announced today the opening of a Phase 2 trial testing G207, an oncolytic HSV immunotherapy, in pediatric brain tumor patients.G207 is being evaluated for efficacy...